WALTHAM, Mass.--(BUSINESS WIRE)--Two weeks after the launch announcement of Paradigm4’s Precision Medicine platform and its early adopters, Paradigm4 is announcing that another top 15 pharma company has selected Paradigm4 to exploit the power of the UK Biobank data.
Paradigm4’s newly launched REVEAL™ Translational Informatics Platform with its PheGe™ Browser enables bioinformaticians and scientists to readily work with the scale and diversity of public and proprietary multi-omics, behavioral, clinical, health outcomes, and environmental data generated today. Built on Paradigm4’s scientific data computational engine for complex data analysis and machine learning, REVEAL™ accelerates integrative, multi-modal, longitudinal, population-scale data science exploration and discovery.
“The absolute scale and diversity of the data in the UK Biobank will drive transformational GWAS/PheWAS research,” said Paradigm4’s CEO Marilyn Matz. “Our aggressive timelines provide biopharma customers with best-in-class performance and services to rapidly mine this valuable data set.”
“The UK Biobank dataset redefines our view of Real World Evidence to support active clinical development projects where new insights into cohort selection for recruiting or stratifying patients are very valuable,” added Zachary Pitluk, Ph.D., V.P. of Life Sciences. “The UK Biobank data in REVEAL™ is a unique resource for in-silico trial simulations with its ease of data selection and support for optimizing machine learning parameters. Enabling our customers with a truly private analytical environment offers a distinct advantage in a competitive market like drug development.”
Paradigm4, a scientific information solutions provider, advances scientific and engineering insights by enabling scientists and data scientists to take full advantage of the scale, resolution, and diversity of public and proprietary scientific data to accelerate their research. Leading Life Sciences, IoT, instrument, and research institutes use Paradigm4’s REVEAL™ discovery engine for collaborative, reproducible research. The company was founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker.